ClinicalTrials.gg
RecruitingNCT06000761Updated Jul 8, 2026

Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit

An interventional study of Standardized oral Care in Ventilator Associated Pneumonia, Bronchopulmonary Dysplasia and Respiratory Disease, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 1 Hour to 3 Days. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by University of Florida · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
1 Hour to 3 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 62 studies in Pneumonia, Ventilator-Associated with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pneumonia, Ventilator-Associated · United States.

Planned enrollment
16th of 49
218 · median 149
Started
2023
with 3 others
No phase
20 of 62
2 open now
Registered
60th of 62
by date

Among the 62 studies in Pneumonia, Ventilator-Associated with a site in United States, this one is the 16th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2023, is one of 20 with no phase, and was the 60th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

4 of the 62 studies in Pneumonia, Ventilator-Associated with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 1 Hour to 3 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Pneumonia, Ventilator-Associated with a site in United States, or all of them as a file.
02

Study summary

Premature infants are susceptible to complications related to infrequent and non-standardized oral care. Although the benefits of frequent standardized oral care are known to reduce oral dysbiosis (increased level of potentially pathogenic bacteria) and its associated complications in critically ill adults leading to established evidence-based guidelines, no such information exists for VLBW infants. The proposed study will prospectively follow 168 VLBW infants for 4 weeks following birth.

Read the detailed description

Premature very low birth weight (VLBW) infants are susceptible to complications related to infrequent and non-standardized oral care. Although the benefits of frequent standardized oral care are known to reduce oral dysbiosis (increased level of potentially pathogenic bacteria) and its associated complications in critically ill adults leading to established evidence-based guidelines, no such information exists for VLBW infants. Premature VLBW infants are highly susceptible to costly, life threatening and potentially preventable morbidities, such as ventilator associated pneumonia (VAP), bronchopulmonary dysplasia (BPD; oxygen requirement at 28 days of life) and need for prolonged respiratory support which require additional treatments, increase cost of care, and can lead to chronic illness, re-hospitalization, and developmental delay. A dearth of information exists regarding oral care in VLBW infants, and no such guidelines exist for infants admitted to the neonatal intensive care unit (NICU) which may negatively affect their health. Thus, research regarding the effect of frequent, standardized oral care on the health of VLBW infants is essential to develop guidelines thus potentially improving the health of this vulnerable population. If successful, this research could change practice in NICUs across the nation.

03

Conditions studied

  • Ventilator Associated Pneumonia
  • Bronchopulmonary Dysplasia
  • Respiratory Disease
04

Who can participate

Ages eligible
1 Hour to 3 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mother ≥18 years of age
  • ≤ 30 weeks gestation
  • Born weighing ≤ 1500 grams

Exclusion criteria

Exclusion:

  • Congenital anomalies of the face, lungs, or gastrointestinal system
  • Not expected to live > 7 days following delivery.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
218 participants (estimated)

Study arms

  • Active comparator
    Group 1

    Standardized oral care performed every 3-4 hours using human milk, donor or breast milk.

    Procedure: Standardized oral Care

  • Active comparator
    Group 2

    Standardized oral care performed every 3-4 hours using sterile water.

    Procedure: Standardized oral Care

  • Active comparator
    Group 3

    Standardized oral care performed every 12 hours using sterile water.

    Procedure: Standardized oral Care

Interventions

  • ProcedureStandardized oral Care

    One sponge-tipped swab, saturated with sterile water or human milk, will used clean the oral cavity with 15 seconds each area. Surfaces include all 4 quadrants of the gum surface and upper posterior part of the oropharynx. A second swab, with sterile water or milk will be used on the ventral and posterior surfaces of the tongue. A third swab, saturated with sterile water or human milk, will be used to clean the outer surface of any dwelling oral tubes (endotracheal tube, NAVA or feeding tube). Lips will be cleaned with a sterile gauze saturated with sterile water or human milk. Oral cavity will be suctioned as needed with an oral suction devise to remove secretions.

06

What researchers measure

Primary outcomes

  1. Number of participants with oral microbiome dysbiosis.

    Oral samples will be obtained weekly and the microbiome analyzed using rRNA 16s sequencing

    Time frame: 0-28 days

Secondary outcomes

  1. Number of participants with ventilator associated pneumonia

    Evidence of ventilator pneumonia will be assessed weekly over the first 4 weeks of life

    Time frame: 0-28 days

  2. Number of participants with bronchopulmonary dysplasia

    Evidence of bronchopulmonary dysplasia will be assessed weekly over the first 60 days of life

    Time frame: 0-60 days

  3. Number of days requiring respiratory support

    Days the infant was on any type of respiratory support will be assessed daily for the first 60 days of life

    Time frame: 0-60 days

07

Study locations

1 of 1 sites recruiting
  • Neonatal intensive care unit at Shands children's hospital at the Univeristy of Florida
    Gainesville, Florida 32504, United States
    Recruiting
    • Leslie A Parker, PhD · Contactparkela@ufl.edu · 352-215-9360
    • Leslie A Parker, PhD · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Sep 2026, 34 months after the start.

Of 82 non-industry interventional studies with no phase under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's planned 34 months is above that.

Counting every sponsor, half of 83 studies reached it within 20 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 21, 2023
StartActual
Nov 23, 2023
Primary completionEst.
Sep 23, 2026
CompletionEst.
Dec 20, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06000761
Collaborators
The Gerber Foundation
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Nov 23, 2023
Primary completion
Sep 23, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Jul 8, 2026

Study contacts

Leslie A Parker, PhD, APRN
Contact
parkela@ufl.edu
352-273-6384
Leslie Parker, PHD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion